Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Davide Melisi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-4031-7585; OpenAlex author ID A5049680516. Sources: OpenAlex.

Their work

Papers
58 (first author 6, last author 20)
Trials
0
Grants
0
Labs led
1
Collaborators
185
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 4 papers · 2018: 6 papers · 2019: 5 papers · 2020: 9 papers · 2021: 3 papers · 2022: 1 paper · 2023: 3 papers · 2024: 6 papers · 2025: 4 papers · 2026: 9 papers

Papers 50 of 58

  1. Targeted therapeutic strategies in rare subtypes of pancreatic cancer: Histology, molecular profiles, and emerging opportunities. Last author DOI 10.1016/j.ctrv.2026.103123↗
  2. Second-line liposomal irinotecan plus S-1 vs. liposomal irinotecan plus 5-fluorouracil in metastatic pancreatic cancer: The phase I/II randomized NAPAN trial. Co-author DOI 10.1016/j.ejca.2026.116683↗
  3. NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI … Last author DOI 10.1016/j.esmoop.2025.106043↗
  4. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: updated analysis of survival and circulating and genetic biomarkers from … Last author DOI 10.1016/j.esmoop.2026.106964↗
  5. Response to Letter to the Editor: 'NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgr… Last author DOI 10.1016/j.esmoop.2026.108307↗
  6. CT texture analysis and delta radiomics in predicting R0 resection after preoperative chemotherapy in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2026.102900↗
  7. EGFR ligand Angiogenin predicts response to ALK5 inhibition in pancreatic cancer via a TNF-α paracrine axis in tumor-associated macrophages. Last author DOI 10.1038/s41388-026-03774-0↗
  8. Author Correction: CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages. Last author DOI 10.1038/s41698-026-01442-w↗
  9. Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection. Co-author DOI 10.1093/oncolo/oyag085↗
  10. Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study. Co-author DOI 10.1016/j.ejso.2024.109544↗
  11. Early-onset enriches the identification of actionable alterations in patients with KRAS wild-type pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.esmogo.2025.100179↗
  12. Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic… Co-author DOI 10.1016/j.esmoop.2025.105534↗
  13. A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3). First author DOI 10.1080/14796694.2025.2458458↗
  14. Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment. Last author DOI 10.1002/cam4.7345↗
  15. Circumventing human limits in precision oncology: AI-enhanced tailoring of post-operative treatment for pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.annonc.2024.05.547↗
  16. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial. Co-author DOI 10.1016/j.ejca.2023.113430↗
  17. CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages. Last author DOI 10.1038/s41698-024-00742-3↗
  18. Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/0008-5472.can-23-0104↗
  19. Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear. Co-author DOI 10.1177/17588359241234487↗
  20. The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.6111↗
  21. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-lab… First author DOI 10.1016/s0140-6736(23)01366-1↗
  22. Timing of Initiation of Palliative Chemotherapy in Asymptomatic Patients with Metastatic Pancreatic Cancer: An International Expert Survey and Case-Vignette St… Co-author DOI 10.3390/cancers15235603↗
  23. Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer. Last author DOI 10.3389/fsurg.2022.866173↗
  24. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. Co-author DOI 10.1016/j.esmoop.2020.100032↗
  25. Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. Co-author DOI 10.1136/jitc-2020-002068↗
  26. Chart review of diagnostic methods, baseline characteristics and symptoms for European patients with pancreatic cancer. First author DOI 10.2217/fon-2020-0749↗
  27. Correlation of MR features and histogram-derived parameters with aggressiveness and outcomes after resection in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00261-020-02509-3↗
  28. First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observa… Co-author DOI 10.1136/esmoopen-2019-000587↗
  29. Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-20-0395↗
  30. Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer. Last author DOI 10.1158/1535-7163.mct-19-0270↗
  31. A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. Last author DOI 10.1177/1758835920947969↗
  32. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. Co-author DOI 10.1186/s13046-020-01732-6↗
  33. Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-020-08515-5↗
  34. Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients. Last author DOI 10.3390/cancers12051131↗
  35. From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer. Co-author DOI 10.3390/cells9020309↗
  36. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2019.2277↗
  37. TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer. Co-author DOI 10.1007/s00280-019-03807-4↗
  38. Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cance… Co-author DOI 10.1007/s00280-019-03931-1↗
  39. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin. Co-author DOI 10.1016/j.ejca.2018.09.029↗
  40. Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-19-0187↗
  41. Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results. Co-author DOI 10.1016/j.pan.2018.04.002↗
  42. Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling. Last author DOI 10.1038/ijo.2017.285↗
  43. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. Co-author DOI 10.1038/s41416-018-0246-z↗
  44. Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy. Co-author DOI 10.1038/s41430-018-0155-5↗
  45. MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity. Last author DOI 10.21873/anticanres.12431↗
  46. Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance. Co-author DOI 10.3390/ijms19113331↗
  47. Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? Co-author DOI 10.1016/j.critrevonc.2017.03.025↗
  48. Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based … Co-author DOI 10.1038/bjc.2017.67↗
  49. A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma. Last author DOI 10.1080/2162402x.2017.1322242↗
  50. EMT and Treatment Resistance in Pancreatic Cancer. First author DOI 10.3390/cancers9090122↗

Closest collaborators

The 25 strongest of 185 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Simona Casalino · 16 shared papers, 2020–2026 · strength 3.29
  2. Valeria Merz · 18 shared papers, 2017–2026 · strength 2.60
  3. Teresa Mercade Macarulla · 13 shared papers, 2018–2026 · strength 2.03
  4. Silvia Pietrobono · 9 shared papers, 2022–2026 · strength 1.96
  5. Enza Scarlato · 7 shared papers, 2024–2026 · strength 1.91
  6. Eileen Mary O'Reilly · 6 shared papers, 2023–2026 · strength 1.16
  7. Richard A Hubner · 7 shared papers, 2017–2026 · strength 1.14
  8. Zev A. Wainberg · 5 shared papers, 2023–2026 · strength 0.99
  9. Andrew Scott Paulson · 5 shared papers, 2023–2026 · strength 0.99
  10. Roberto Pazo-Cid · 5 shared papers, 2023–2026 · strength 0.99
  11. Tanios Bekaii‐Saab · 5 shared papers, 2023–2026 · strength 0.99
  12. Shubham Pant · 5 shared papers, 2023–2026 · strength 0.99
  13. Eric Van Cutsem · 5 shared papers, 2023–2026 · strength 0.99
  14. Giampaolo Tortora · 11 shared papers, 2011–2026 · strength 0.96
  15. Giuseppe Malleo · 8 shared papers, 2017–2026 · strength 0.88
  16. Michèle Milella · 9 shared papers, 2011–2024 · strength 0.86
  17. Roberto Salvia · 7 shared papers, 2018–2026 · strength 0.79
  18. Mirko D’Onofrio · 6 shared papers, 2018–2026 · strength 0.75
  19. Giovanni Butturini · 4 shared papers, 2020–2026 · strength 0.73
  20. Francesca Simionato · 9 shared papers, 2017–2020 · strength 0.70
  21. Aldo Scarpa · 8 shared papers, 2015–2024 · strength 0.67
  22. Riccardo De Robertis · 4 shared papers, 2018–2026 · strength 0.61
  23. Raffaela Santoro · 7 shared papers, 2017–2020 · strength 0.60
  24. Johanna W. Wilmink · 3 shared papers, 2023–2026 · strength 0.60
  25. Sara Lonardi · 4 shared papers, 2020–2026 · strength 0.58

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.